Actos Lawsuit Evaluation | Actos Bladder Cancer Lawsuit

Actos Bladder Cancer Lawsuit Alleges “Willful and Wanton Malice”

Staff Writer | February 10th, 2012

On January 23, 2012, West Virginia resident Shirley Miller filed an Actos bladder cancer lawsuit against Takeda Pharmaceuticals in the Circuit Court of Cook County, Illinois. The plaintiff requests compensation for personal injuries suffered as a proximate result of taking the “defective and unreasonably dangerous drug Actos.”

Miller’s Actos side effects lawsuit cites several studies, FDA warnings and other evidence linking the diabetes drug to an increased risk for bladder cancer. Miller was diagnosed with bladder cancer on or around November 2008.

Actos lawsuit evaluation sought by bladder cancer victims

In 2005 – six years after Actos had been approved for use in the United States – results from the PROactive three-year study were published. Miller’s Actos bladder cancer lawsuit alleges that during the course of the study, researchers and Takeda Pharmaceuticals became aware that patients receiving Actos showed a statistically significant higher percentage of bladder cancer, as compared to those taking similar medications.

Plaintiffs who have filed cases after undergoing an Actos lawsuit evaluation have also cited other research, including a three-year liver safety study that also revealed a higher percentage of bladder cancer in patients receiving Actos.

On June 15, 2011, the FDA issued a safety announcement regarding the risk of Actos bladder cancer. According to the health agency, the “use of the diabetes medication Actos (pioglitazone) for more than one year may be associated with an increased risk of bladder cancer.” The FDA elaborated that exposure to pioglitazone therapy for more than 12 months was associated with a 40% increased risk.

Actos lawsuit evaluation: did Takeda act with malice?

Miller’s Actos bladder cancer lawsuit alleges that Takeda Pharmaceuticals failed to inform medical professionals and consumers about the increased risks associated with the drug. In fact, Miller’s lawsuit alleges that the defendants “willfully, wantonly and with malice withheld the knowledge of increased risk of cancer in users of Actos to prevent any chances of its products’ registrations being delayed or rejected” by the FDA. Actos is the tenth best-selling drug in the United States.

Affected patients seek Actos lawsuit evaluation

Patients who have been diagnosed with side effects such as Actos bladder cancer have consulted a qualified attorney for an Actos lawsuit evaluation.

As with plaintiff Miller, they may go on to seek compensation for mental and physical pain and suffering, ongoing medical treatment, loss of income and earning capacity, disability, and emotional distress.